UnitedHealth raises 2026 guidance to $19.50–$20.00/share, announces ACA profit rebate

UnitedHealth Group raised its full-year 2026 adjusted earnings guidance to $19.50–$20.00 per share, up from the prior range of >$17.75 per share disclosed in January 2026. Second quarter 2026 revenues were $112.0 billion, with adjusted earnings of $6.38 per share. The medical care ratio improved to 86.7% from 89.4% in Q2 2025, driven by benefit design changes, pricing discipline, and medical cost management.

The company announced it will eliminate and rebate all profits from individual ACA coverage in 2026, returning funds to approximately 1 million members. This is a voluntary action taken while Congress works on longer-term ACA reforms. The move addresses affordability concerns and may reduce near-term profitability from this segment.

UnitedHealth Group committed $1 billion to the United Health Foundation to expand priorities including rural health, maternal and children's health, and behavioral health. The 8-K notes that for the six months ended June 30, 2026, restructuring and other items included a contribution to the United Health Foundation of $400 million funded by the cash gain on the disposition of an Optum Insight business.

The company announced sweeping reforms to simplify care delivery and reduce costs. It will eliminate 30% of prior approval volume by year-end 2026, including nearly two-thirds of pediatric prior approvals. On the pharmacy side, it launched a fully transparent, fee-based PBM model that decouples pricing from drug list prices and prescription volume, and committed to 100% pass-through of manufacturer rebates to clients by January 1, 2028. These changes aim to improve the patient and provider experience and address industry criticism of PBM practices.

UnitedHealth Group reported second quarter 2026 revenues of $112.0 billion and operating earnings of $8.0 billion, with a 4.9% net margin. The company raised its full-year 2026 adjusted earnings guidance to $19.50–$20.00 per share, up from the prior range of >$17.75 per share, reflecting strong year-to-date performance and an improved outlook for the remainder of the year.

The medical care ratio improved to 86.7% in Q2 2026 from 89.4% in Q2 2025, driven by benefit design changes, pricing discipline, member mix, and medical cost management initiatives. The quarter included $860 million of net favorable prior period development, mostly related to 2026 dates of service. The company updated its full-year 2026 MCR guidance to 88.1% ± 25 basis points, tightening from the prior 88.8% ± 50 basis points.

UnitedHealth Group generated $11.1 billion in operating cash flow in Q2 2026, representing 1.9 times net income, reflecting strong earnings and disciplined working capital management. The debt-to-capital ratio improved to 41.2% from 44.1% a year earlier. The company has repurchased $4.0 billion of stock through mid-July 2026 and expects to repurchase at least $5.0 billion for the full year, doubling the prior guidance of ~$2.5 billion.

UnitedHealthcare's total membership declined by 525,000 sequentially to 48.5 million in Q2 2026. Medicare Advantage membership contracted by 965,000 since year-end 2025, while Community & State membership declined by 380,000 in the quarter, primarily due to the planned Louisiana health plan exit and ongoing Medicaid eligibility requirements. Despite the membership declines, UnitedHealthcare's operating earnings increased to $3.9 billion with a 4.6% margin, up from $2.1 billion and 2.4% in Q2 2025.

UnitedHealth Group announced a broad set of healthcare reform initiatives, including voluntarily eliminating and rebating profits from individual ACA coverage in 2026 (affecting ~1 million members), committing $1 billion to the United Health Foundation for rural health, maternal/children's health, and behavioral health initiatives, and eliminating 30% of current prior approval volume by year-end 2026. The company also announced support for 1,500 rural hospitals through accelerated payments and reduced prior approval requirements, and committed to 100% pass-through of manufacturer drug rebate discounts to clients by January 1, 2028.

The company disclosed its second quarter 2026 financial results through a press release. The 8-K body itself does not contain the actual financial metrics—those are in the attached exhibits (99.1 and 99.2), which are furnished but not filed. This is a standard earnings announcement filing structure.